Deutsche Bank has downgraded its profit forecast for Sinopharm from 2024 to 2030 by 4% to 10%.
According to the Securities Times app, Deutsche Bank released a research report stating that Sinopharm (01099) announced its third-quarter performance. Due to the decrease in revenue and gross margin, its profit forecast for 2024 to 2030 has been reduced by 4% to 10%. The target price and scenario value are lowered by 4 to 9%. The bank has lowered Sinopharm's target price from 25 Hong Kong dollars to 24 Hong Kong dollars, equivalent to a forecast price-earnings ratio of 7.9 times next year, with a rating of 'shareholding'.
